ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

ADIENNE aims to develop a range of product candidates for orphan diseases for which existing treatment options are limited, the patient population is small and the clinical needs for therapies is high.

TEPADINA® has recently obtained an extension of the marketing authorisation from EMA

Lugano (Switzerland), January 28, 2021

ADIENNE Pharma & Biotech SA is pleased to announce that its pharmaceutical product TEPADINA® has recently obtained an extension of the marketing authorisation from EMA concerning:
- a new strength: 400mg in 400 ml bag, concentration 1 mg/ml
- a new pharmaceutical form: Powder and solvent for solution for infusion..

Click HERE to read the full news.

Accord and ADIENNE Enter into Distribution Agreement for PHELINUN

Lugano, Switzerland, 16 February 2021

Accord Healthcare Limited (“Accord”) and ADIENNE Pharma & Biotech S.A. (“ADIENNE”) have entered into a licensing and distribution agreement for the commercialisation of PHELINUN (melphalan hydrochloride) 200 mg vials.

Click HERE to read the full news.